Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.

Goetz IA, Kanu C, Hoover A, Jimenez-Moreno C, Karn H, Kimel M, Neff LM, Boye KS

Obesity pillars24 Oct 2025Cited by 3 (Europe PMC)

PMID41216380PMCIDPMC12596213DOI10.1016/j.obpill.2025.100220PepBankPUB-41216380

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanObservational studyOther
Thirty-one of 36 retatrutide-treated adults with obesity or overweight reported changes in eating behaviors within the first 8 weeks.
In plain wordsThirty-one of 36 adults treated with retatrutide said their eating behaviour changed in the first 8 weeks.
Peptide
Retatrutide
Outcome
Not applicableChange in eating behaviors within 8 weeks
Study
n = 36
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1, 4, 8 and 12 mg · first 8 weeksAs given in this study (human).
Source sentences
Summary
Thirty-one of 36 retatrutide-treated participants reported changes in eating behaviors within the trial's first 8 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were adults with obesity or overweight and weight-related complications exiting the phase 2, double-blind, placebo-controlled trial of retatrutide (1, 4, 8, and 12 mg) (NCT04881760).
Summary · context
Participants (N = 40; mean age 51 years; 52.5 % male) received retatrutide 4/8/12 mg (n = 23), retatrutide 1 mg (n = 13), or placebo (n = 4).
Report a problemFND-4121638001
02HumanObservational studyOther
Participants described eating less often or in smaller portions, feeling hungry less often, feeling full after eating, different food preferences and more control over eating.
In plain wordsParticipants said they ate less often or less per meal, felt hungry less, felt full sooner and felt more in control of eating.
Peptide
Retatrutide
Outcome
Not applicableDescribed eating changes
Study
n = 36
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1, 4, 8 and 12 mgAs given in this study (human).
Source sentences
Summary
Participants described eating less often or smaller portions, feeling hungry less often, feeling full after eating, having different food preferences, and feeling more in control of their eating.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were adults with obesity or overweight and weight-related complications exiting the phase 2, double-blind, placebo-controlled trial of retatrutide (1, 4, 8, and 12 mg) (NCT04881760).
Summary · context
Participants (N = 40; mean age 51 years; 52.5 % male) received retatrutide 4/8/12 mg (n = 23), retatrutide 1 mg (n = 13), or placebo (n = 4).
Report a problemFND-4121638002
03HumanObservational studyOther
Of the retatrutide-treated participants, 32 described feeling good about themselves or self-confident.
In plain wordsThirty-two retatrutide-treated participants said they felt good about themselves or self-confident.
Peptide
Retatrutide
Outcome
Not applicableFeeling good about themselves or self-confident
Study
n = 36
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
1, 4, 8 and 12 mgAs given in this study (human).
Measurements
Participants reporting
32 participants
self-confident
Source sentences
Summary
feeling good about themselves or self-confident (n = 32)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were adults with obesity or overweight and weight-related complications exiting the phase 2, double-blind, placebo-controlled trial of retatrutide (1, 4, 8, and 12 mg) (NCT04881760).
Summary · context
Participants (N = 40; mean age 51 years; 52.5 % male) received retatrutide 4/8/12 mg (n = 23), retatrutide 1 mg (n = 13), or placebo (n = 4).
Report a problemFND-4121638003
04HumanObservational studyOther
Of the retatrutide-treated participants, 25 described feeling happy.
In plain wordsTwenty-five retatrutide-treated participants said they felt happy.
Peptide
Retatrutide
Outcome
Not applicableFeeling happy
Study
n = 36
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
1, 4, 8 and 12 mgAs given in this study (human).
Measurements
Participants reporting
25 participants
feeling happy
Source sentences
Summary
feeling happy (n = 25).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were adults with obesity or overweight and weight-related complications exiting the phase 2, double-blind, placebo-controlled trial of retatrutide (1, 4, 8, and 12 mg) (NCT04881760).
Summary · context
Participants (N = 40; mean age 51 years; 52.5 % male) received retatrutide 4/8/12 mg (n = 23), retatrutide 1 mg (n = 13), or placebo (n = 4).
Report a problemFND-4121638004
05HumanObservational studyOther
Of the retatrutide-treated participants, 27 reported improvements in mobility or ability to perform physical activities.
In plain wordsTwenty-seven retatrutide-treated participants reported better mobility or ability to do physical activities.
Peptide
Retatrutide
Outcome
Not applicableImproved mobility or physical activity
Study
n = 36
Outcome group
Exercise and physical function · Whole body
Studied dose
1, 4, 8 and 12 mgAs given in this study (human).
Measurements
Participants reporting
27 participants
mobility or physical activities
Source sentences
Summary
improvements in mobility or ability to perform physical activities (n = 27)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were adults with obesity or overweight and weight-related complications exiting the phase 2, double-blind, placebo-controlled trial of retatrutide (1, 4, 8, and 12 mg) (NCT04881760).
Summary · context
Participants (N = 40; mean age 51 years; 52.5 % male) received retatrutide 4/8/12 mg (n = 23), retatrutide 1 mg (n = 13), or placebo (n = 4).
Report a problemFND-4121638005
06HumanObservational studyOther
Of the retatrutide-treated participants, 24 reported improved energy levels.
In plain wordsTwenty-four retatrutide-treated participants reported better energy levels.
Peptide
Retatrutide
Outcome
Not applicableImproved energy levels
Study
n = 36
Outcome group
Exercise and physical function · Whole body
Studied dose
1, 4, 8 and 12 mgAs given in this study (human).
Measurements
Participants reporting
24 participants
energy levels
Source sentences
Summary
energy levels (n = 24)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were adults with obesity or overweight and weight-related complications exiting the phase 2, double-blind, placebo-controlled trial of retatrutide (1, 4, 8, and 12 mg) (NCT04881760).
Summary · context
Participants (N = 40; mean age 51 years; 52.5 % male) received retatrutide 4/8/12 mg (n = 23), retatrutide 1 mg (n = 13), or placebo (n = 4).
Report a problemFND-4121638006
07HumanObservational studyOther
Of the retatrutide-treated participants, 18 reported improvements in social activities involving food.
In plain wordsEighteen retatrutide-treated participants reported improvements in social activities involving food.
Peptide
Retatrutide
Outcome
Not applicableImproved social activities involving food
Study
n = 36
Outcome group
Exercise and physical function · Whole body
Studied dose
1, 4, 8 and 12 mgAs given in this study (human).
Measurements
Participants reporting
18 participants
social activities involving food
Source sentences
Summary
social activities involving food (n = 18)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were adults with obesity or overweight and weight-related complications exiting the phase 2, double-blind, placebo-controlled trial of retatrutide (1, 4, 8, and 12 mg) (NCT04881760).
Summary · context
Participants (N = 40; mean age 51 years; 52.5 % male) received retatrutide 4/8/12 mg (n = 23), retatrutide 1 mg (n = 13), or placebo (n = 4).
Report a problemFND-4121638007
08HumanObservational studyOther
Of the retatrutide-treated participants, 19 reported improvements in exercise.
In plain wordsNineteen retatrutide-treated participants reported improvements in exercise.
Peptide
Retatrutide
Outcome
Not applicableImproved exercise
Study
n = 36
Outcome group
Exercise and physical function · Whole body
Studied dose
1, 4, 8 and 12 mgAs given in this study (human).
Measurements
Participants reporting
19 participants
exercise
Source sentences
Summary
exercise (n = 19)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were adults with obesity or overweight and weight-related complications exiting the phase 2, double-blind, placebo-controlled trial of retatrutide (1, 4, 8, and 12 mg) (NCT04881760).
Summary · context
Participants (N = 40; mean age 51 years; 52.5 % male) received retatrutide 4/8/12 mg (n = 23), retatrutide 1 mg (n = 13), or placebo (n = 4).
Report a problemFND-4121638008
09HumanObservational studyOther
Of the retatrutide-treated participants, 17 reported improvements in leisure activities.
In plain wordsSeventeen retatrutide-treated participants reported improvements in leisure activities.
Peptide
Retatrutide
Outcome
Not applicableImproved leisure activities
Study
n = 36
Outcome group
Exercise and physical function · Whole body
Studied dose
1, 4, 8 and 12 mgAs given in this study (human).
Measurements
Participants reporting
17 participants
leisure activities
Source sentences
Summary
leisure activities (n = 17)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were adults with obesity or overweight and weight-related complications exiting the phase 2, double-blind, placebo-controlled trial of retatrutide (1, 4, 8, and 12 mg) (NCT04881760).
Summary · context
Participants (N = 40; mean age 51 years; 52.5 % male) received retatrutide 4/8/12 mg (n = 23), retatrutide 1 mg (n = 13), or placebo (n = 4).
Report a problemFND-4121638009
10HumanObservational studyOther
Of the retatrutide-treated participants, 24 reported a reduction in clothing size.
In plain wordsTwenty-four retatrutide-treated participants reported a smaller clothing size.
Peptide
Retatrutide
Outcome
Not applicableReduction in clothing size
Study
n = 36
Outcome group
Body weight · Metabolic and weight
Studied dose
1, 4, 8 and 12 mgAs given in this study (human).
Measurements
Participants reporting
24 participants
clothing size reduction
Source sentences
Summary
reduction in clothing size (n = 24)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were adults with obesity or overweight and weight-related complications exiting the phase 2, double-blind, placebo-controlled trial of retatrutide (1, 4, 8, and 12 mg) (NCT04881760).
Summary · context
Participants (N = 40; mean age 51 years; 52.5 % male) received retatrutide 4/8/12 mg (n = 23), retatrutide 1 mg (n = 13), or placebo (n = 4).
Report a problemFND-4121638010
11HumanObservational studyOther
Two retatrutide-treated participants reported reduced participation in social activities because of adverse events.
In plain wordsTwo retatrutide-treated participants said adverse events made them take part less in social activities.
Peptide
Retatrutide
Outcome
Not applicableReduced social participation due to adverse events
Study
n = 36
Outcome group
Adverse events · Whole body
Studied dose
1, 4, 8 and 12 mgAs given in this study (human).
Measurements
Participants reporting
2 participants
reduced social participation due to adverse events
Source sentences
Summary
reduced participation in social activities due to adverse events (n = 2)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were adults with obesity or overweight and weight-related complications exiting the phase 2, double-blind, placebo-controlled trial of retatrutide (1, 4, 8, and 12 mg) (NCT04881760).
Summary · context
Participants (N = 40; mean age 51 years; 52.5 % male) received retatrutide 4/8/12 mg (n = 23), retatrutide 1 mg (n = 13), or placebo (n = 4).
Report a problemFND-4121638011
12HumanObservational studyOther
Two retatrutide-treated participants reported reduced participation in social activities because of new eating habits.
In plain wordsTwo retatrutide-treated participants said new eating habits made them take part less in social activities.
Peptide
Retatrutide
Outcome
Not applicableReduced social participation due to new eating habits
Study
n = 36
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1, 4, 8 and 12 mgAs given in this study (human).
Measurements
Participants reporting
2 participants
reduced social participation due to new eating habits
Source sentences
Summary
new eating habits (n = 2)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were adults with obesity or overweight and weight-related complications exiting the phase 2, double-blind, placebo-controlled trial of retatrutide (1, 4, 8, and 12 mg) (NCT04881760).
Summary · context
Participants (N = 40; mean age 51 years; 52.5 % male) received retatrutide 4/8/12 mg (n = 23), retatrutide 1 mg (n = 13), or placebo (n = 4).
Report a problemFND-4121638012
13HumanObservational studyOther
Three retatrutide-treated participants reported frustration due to disappointing weight loss.
In plain wordsThree retatrutide-treated participants said they felt frustrated by disappointing weight loss.
Peptide
Retatrutide
Outcome
Not applicableFrustration due to disappointing weight loss
Study
n = 36
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
1, 4, 8 and 12 mgAs given in this study (human).
Measurements
Participants reporting
3 participants
frustration due to disappointing weight loss
Source sentences
Summary
frustration due to disappointing weight loss (n = 3)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were adults with obesity or overweight and weight-related complications exiting the phase 2, double-blind, placebo-controlled trial of retatrutide (1, 4, 8, and 12 mg) (NCT04881760).
Summary · context
Participants (N = 40; mean age 51 years; 52.5 % male) received retatrutide 4/8/12 mg (n = 23), retatrutide 1 mg (n = 13), or placebo (n = 4).
Report a problemFND-4121638013
14HumanObservational studyOther
Of thirty retatrutide-treated participants who had weight reduction as a goal, 76.7% reported achieving their goal.
In plain wordsAmong thirty retatrutide-treated participants who wanted to lose weight, 76.7% said they reached their goal.
Peptide
Retatrutide
Outcome
Not applicableWeight reduction goal achievement
Study
n = 30
Outcome group
Body weight · Metabolic and weight
Studied dose
1, 4, 8 and 12 mgAs given in this study (human).
Measurements
Participants reporting goal achieved
76.7%
participants with a weight reduction goal
Source sentences
Summary
Thirty of 36 retatrutide-treated participants had weight reduction as a goal, and 76.7 % reported achieving their goal.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were adults with obesity or overweight and weight-related complications exiting the phase 2, double-blind, placebo-controlled trial of retatrutide (1, 4, 8, and 12 mg) (NCT04881760).
Summary · context
Participants (N = 40; mean age 51 years; 52.5 % male) received retatrutide 4/8/12 mg (n = 23), retatrutide 1 mg (n = 13), or placebo (n = 4).
Report a problemFND-4121638014

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.